Christopher Haqq, EVP, R&D & Chief Scientific Of at Atara Biotherapeutics, Inc. (ATRA), sold 26,262 shares at $38.04 ($1.0M) on 2019-02-06, disclosed to the SEC on 2019-02-08.
Seasonal sale ($1.0M) by EVP, R&D & Chief Scientific Of — this insider has traded ATRA in February in at least three consecutive prior years. Pattern-driven, low signal.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $38.04 | 2,677 | $102K | 10.0% |
| 2 | $38.04 | 2,677 | $102K | 10.0% |
| 3 | $38.47 | 1,512 | $58K | 5.7% |
| 4 | $38.78 | 9,698 | $376K | 37.1% |
| 5 | $38.78 | 9,698 | $376K | 37.1% |
| Total | $38.61 avg | 26,262 |
| $1.0M |
| 100% |
| Filing → |
| ATRA | SELL | 2018-11-15 | $26K | — | Filing → |
| ATRA | SELL | 2018-09-27 | $582K | — | Filing → |
| ATRA | SELL | 2018-09-25 | $2.0M | — | Filing → |